KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Equity Income (2020 - 2025)

Inovio Pharmaceuticals' Equity Income history spans 6 years, with the latest figure at $205548.0 for Q3 2025.

  • For Q3 2025, Equity Income fell 84.55% year-over-year to $205548.0; the TTM value through Sep 2025 reached $1.4 million, down 63.34%, while the annual FY2024 figure was $2.1 million, 64.5% down from the prior year.
  • Equity Income for Q3 2025 was $205548.0 at Inovio Pharmaceuticals, down from $759000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $3.2 million in Q1 2023 and bottomed at -$4.2 million in Q1 2021.
  • The 5-year median for Equity Income is $266314.0 (2024), against an average of $248594.7.
  • The largest annual shift saw Equity Income plummeted 302.24% in 2022 before it surged 3745.53% in 2025.
  • A 5-year view of Equity Income shows it stood at $732377.0 in 2021, then soared by 281.61% to $2.8 million in 2022, then tumbled by 30.99% to $1.9 million in 2023, then plummeted by 86.19% to $266314.0 in 2024, then dropped by 22.82% to $205548.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Equity Income are $205548.0 (Q3 2025), $759000.0 (Q2 2025), and $140234.0 (Q1 2025).